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• Given α-Klotho’s role in mediating FGF23 signalling and that α-
Klotho may be a phosphaturic factor in its own right,3 its
regulation in the face of high circulating FGF23 is of interest.
• The inverse correlation seen between FGF23 and α-Klotho may
suggest that elevated levels of FGF23 in TIO down-regulate α-
Klotho expression in the kidney and parathyroid glands leading
to reduced circulating levels of α-Klotho.
• Such an adaptive mechanism would help partially reduce the
renal phosphate wasting seen in TIO.
• A prospective larger scale study following FGF23 and α-Klotho
levels over time in each patient is required to further evaluate
this potentially key relationship in TIO.
INTRODUCTION
• Tumour induced osteomalacia (TIO) is characterised by high 
circulating levels of fibroblast growth factor 23 (FGF23) due to 
ectopic secretion from typically small endocrine tumors.1
• An abundance of FGF23 drives the hypophosphatemia and low 
1,25-dihydroxy vitamin D levels characteristic of this condition.1
• The single-pass trans-membrane protein α-Klotho is integral for 
FGF23-mediated receptor activation and its downstream 
effects.2
• The regulation of α-Klotho in the face of high circulating FGF23 is 
currently unknown.
• We investigated the relationship between circulating FGF23 and 
α-Klotho in patients with TIO.
• We identified 15 consecutive plasma FGF23 requests in 
subjects with TIO for testing.
• FGF23 was measured using Immutopics C-term ELISA kit and 
soluble α-Klotho was measured using the IBL ELISA kit. 
• Correlations between biochemical variables were examined 
using  Pearson’s product-moment correlation coefficient.
• Statistical significance of the correlation was tested using a 
two-tailed t test.
Figure 1: Graph showing the correlation between the levels of
circulating FGF23 and a-Klotho in patients presenting tumor induced
osteomalacia. There was no significant correlation between the two
variables [r =-0.28; n =15, p =0.3].
• Circulating α-Klotho levels are inversely correlated to FGF23 in
TIO.
• This may suggest there is a compensatory down-regulation of α-
Klotho in TIO to limit the degree of phosphate wasting that is
pathogenic of this condition.
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RESULTS
DISCUSSION
CONCLUSION
• The group consisted of 7 males and 8 females with an age of 53 
± 20 years (mean ± SD).
• Only one subject was not on treatment for TIO at the time of 
sampling.
• The average circulating levels of FGF23 and α-Klotho were 286 ±
244 RU/ml and 644 ± 309 pg/ml respectively.
• Although not significant, there was an inverse correlation 
between FGF23 and α-Klotho circulating levels, with a Pearson 
coefficient of – 0.28.
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Age Sex Source / Other diagnoses FGF23 α-Klotho
70 Male Unknown, prostate cancer 102 486
29 Male Unknown primary 105 834
65 Male Unknown primary 134 807
85 Male Unknown, prostate cancer 149 1350
50 Male Unknown primary 158 384
53 Female Unknown primary 170 339
53 Female Unknown primary 173 474
10 Female Neck haemangioma 444 845
22 Female Unknown primary 217 474
67 Female Unknown primary 221 1191
64 Female Unknown primary 330 819
47 Female Spindle cell lipoma 347 819
70 Male Unknown primary 434 281
50 Female Unknown primary 449 576
68 Male Unknown primary 1104 357
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